ATE502048T1 - Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs - Google Patents

Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs

Info

Publication number
ATE502048T1
ATE502048T1 AT06739100T AT06739100T ATE502048T1 AT E502048 T1 ATE502048 T1 AT E502048T1 AT 06739100 T AT06739100 T AT 06739100T AT 06739100 T AT06739100 T AT 06739100T AT E502048 T1 ATE502048 T1 AT E502048T1
Authority
AT
Austria
Prior art keywords
chlorotoxin conjugate
intraoperative
visibility
cancer
fluorescent
Prior art date
Application number
AT06739100T
Other languages
English (en)
Inventor
Mandana Veiseh
S-Bahram Bahrami
James Olson
Patrik Gabikian
Richard Ellenbogen
Raymond Sze
Omid Veiseh
Miqin Zhang
Original Assignee
Univ Washington
Fred Hutchinson Cancer Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Fred Hutchinson Cancer Res Foundation filed Critical Univ Washington
Application granted granted Critical
Publication of ATE502048T1 publication Critical patent/ATE502048T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/22—Implements for squeezing-off ulcers or the like on inner organs of the body; Implements for scraping-out cavities of body organs, e.g. bones; for invasive removal or destruction of calculus using mechanical vibrations; for removing obstructions in blood vessels, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
AT06739100T 2005-04-22 2006-03-20 Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs ATE502048T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67428005P 2005-04-22 2005-04-22
PCT/US2006/010170 WO2006115633A2 (en) 2005-04-22 2006-03-20 Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer

Publications (1)

Publication Number Publication Date
ATE502048T1 true ATE502048T1 (de) 2011-04-15

Family

ID=36609637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06739100T ATE502048T1 (de) 2005-04-22 2006-03-20 Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs

Country Status (6)

Country Link
US (3) US20070154965A1 (de)
EP (1) EP1877428B1 (de)
AT (1) ATE502048T1 (de)
DE (1) DE602006020710D1 (de)
ES (1) ES2360519T3 (de)
WO (1) WO2006115633A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
ATE502048T1 (de) * 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
ES2390314T3 (es) 2006-02-24 2012-11-08 Medibeacon Development, Llc Agentes ópticos para uso en cirugía
EP2018559A1 (de) * 2006-04-25 2009-01-28 Centre National de la Recherche Scientifique (CNRS) Funktionalisierung von goldnanopartikeln mit ausgerichteten proteinen, anwendung auf die zellmembranenmarkierung mit hoher dichte
KR101578225B1 (ko) 2007-05-16 2015-12-17 지이 헬스케어 에이에스 영상화를 위한 표지된 ｈｇｆ 결합성 펩티드
ATE551605T1 (de) * 2007-07-30 2012-04-15 Univ Arizona Verfahren und vorrichtungen zur erkennung von biofilmen
US20110091380A1 (en) * 2007-08-07 2011-04-21 Transmolecular, Inc. Chlorotoxins as drug carriers
EP2211913A4 (de) * 2007-10-12 2010-12-22 Transmolecular Inc Systemische verabreichung von chlorotoxin-mitteln zur diagnose und behandlung von tumoren
EP3115469B1 (de) * 2007-11-19 2020-04-29 Celera Corporation Lungenkrebsmarker und verwendungen davon
WO2009126835A2 (en) * 2008-04-09 2009-10-15 University Of Washington Techtransfer Invention Licensing Magnetic nanoparticle and method for imaging t cells
CA2758415C (en) * 2008-04-14 2019-06-04 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
EP2335073A4 (de) * 2008-09-02 2012-09-26 Univ Maryland In-vivo-diagnose und behandlung von biofilminfektionen
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
WO2013003507A1 (en) * 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
BR112015013515A2 (pt) 2012-12-10 2017-11-14 Hutchinson Fred Cancer Res métodos de geração de uma biblioteca de candidatos a fármaco definida por massa, e para identificar peptídeos possuindo uma propriedade farmacológica
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
JP6652923B2 (ja) * 2013-09-17 2020-02-26 ブレイズ バイオサイエンス， インコーポレイテッド クロロトキシンコンジュゲート及びその使用方法
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2017180789A2 (en) 2016-04-12 2017-10-19 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6130101A (en) * 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
JP2003509034A (ja) * 1999-09-14 2003-03-11 バイオメディカル アフエレーゼ システム ゲーエムベーハー 生化学活性を有する磁性ナノ粒子、その製造法と使用
AU4305101A (en) * 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
DE10020376A1 (de) * 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
AU2002345959A1 (en) 2001-06-26 2003-01-08 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
US6972326B2 (en) * 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
EP2431385A3 (de) 2002-05-31 2012-07-04 Morphotek, Inc. Kombinationstherapie mit Chlorotoxin
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7560160B2 (en) * 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
WO2005053611A2 (en) 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
EP1756270B1 (de) 2004-04-06 2010-03-03 Transmolecular, Inc. Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
US20080153746A1 (en) 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
GB0422901D0 (en) 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) * 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
ATE502048T1 (de) 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
EP1937824B1 (de) 2005-08-18 2013-03-13 Ambrx, Inc. trna-zusammensetzungen und deren verwendungen
EP2147927A3 (de) 2006-03-31 2010-09-01 Transmolecular, Inc. Verwendung von 131I-TM-601 für die Diagnose und Behandlung von Gliomas
EP2029157A4 (de) 2006-05-19 2009-11-18 Georgia Tech Res Inst Abc-transporterligand
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
US8043829B2 (en) 2006-10-25 2011-10-25 Amgen Inc. DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression
US20090004105A1 (en) 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
US20110091380A1 (en) 2007-08-07 2011-04-21 Transmolecular, Inc. Chlorotoxins as drug carriers
EP2211913A4 (de) 2007-10-12 2010-12-22 Transmolecular Inc Systemische verabreichung von chlorotoxin-mitteln zur diagnose und behandlung von tumoren
WO2009117018A1 (en) 2008-03-20 2009-09-24 Transmolecular, Inc. Inhibition of angiogenesis
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
DK3381933T3 (da) 2008-06-24 2020-08-03 Technische Universität München Muteiner af hngal og relaterede proteiner med affinitet til et givet mål
US20100098637A1 (en) 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
US10191060B2 (en) 2009-11-09 2019-01-29 University Of Washington Functionalized chromophoric polymer dots and bioconjugates thereof
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
CN106995493B (zh) 2010-02-04 2021-09-24 卫材公司 氯毒素多肽和结合物及其应用
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
CA2808392C (en) 2010-08-16 2020-03-10 Pieris Pharmaceuticals Gmbh Binding proteins for hepcidin

Also Published As

Publication number Publication date
EP1877428B1 (de) 2011-03-16
EP1877428A2 (de) 2008-01-16
US20080279780A1 (en) 2008-11-13
ES2360519T3 (es) 2011-06-06
US8778310B2 (en) 2014-07-15
WO2006115633A3 (en) 2006-12-28
DE602006020710D1 (de) 2011-04-28
US20140241993A1 (en) 2014-08-28
US20070154965A1 (en) 2007-07-05
WO2006115633A2 (en) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE502048T1 (de) Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2008022043A3 (en) Intraoperative imaging of renal cortical tumors and cysts
CY1114441T1 (el) Συνδετικες ενωσεις, ανοσογονικες ενωσεις και πεπτιδομιμητικα
TW200716141A (en) Compositions and methods for treatment for neoplasms
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
BRPI0916121A2 (pt) "métodos para identificar câncer de próstata, método para identificar a presença de uma fusão gênica, kit e uso de uma composição"
BRPI0818672A2 (pt) 2'-fluor-2'-desoxitetra-hidrouridinas como inibidores da citidina desaminase
WO2007009755A3 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
ATE527552T1 (de) Mr-darstellungsverfahren zur diskriminierung zwischen gesundem und tumorgewebe
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
CY1111518T1 (el) Tgf βητα 1 ειδικα αντισωματα
WO2007127841A3 (en) Compositions and methods of preparation thereof
EP3005941A3 (de) Intraoperative fluoreszenz-spektroskopie und anwendungen davon
EP1765391A4 (de) Bakterielle zusammensetzungen zur behandlung von krebs
ECSP11011338A (es) Anticuerpos biespecíficos anti-her
PL2260862T3 (pl) Kompozycje i sposoby leczenia nowotworów prezentujących antygeny surwiwinowe
PL1720611T3 (pl) Marker diagnostyczny dla raka
WO2007123880A3 (en) Methods and kits for early stage caries detection
ATE492651T1 (de) Moesin, caveolin 1 und yes-assoziiertes protein 1 als prädiktive marker der reaktion auf dasatinib bei brustkrebs
EP2274437A4 (de) Zusammensetzungen und verfahren zur erkennung von egfr-mutationen bei krebs
WO2008031038A3 (en) Pre- and intra-operative localization of penile sentinel nodes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1877428

Country of ref document: EP